ClinicalTrials.gg
CompletedNCT07129915Updated Nov 19, 2026

Nudge-Based Shared Decision Making and Self-Management in Type 2 Diabetes: A Randomized Trial

An interventional study of Linguistic Nudging Training and Medication Preference App in Diabetes Mellitus, Type 2, Physician-Patient Relations and Self-management, sponsored by Yunxuan Li. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Yunxuan Li · Not applicable, Interventional, and Health services research

How we know

Updated Nov 19, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 913 studies in Diabetes Mellitus, Type 2 with a site in China — 205 open to participants now, 229 under way, 46 of them phase 3. Diabetes Mellitus, Type 2 · China.

Enrollment
303rd of 769
280 · median 192
Started
2025
with 80 others
No phase
195 of 913
55 open now
Registered
781st of 913
by date

Among the 913 studies in Diabetes Mellitus, Type 2 with a site in China, this one is the 303rd largest by enrollment of the 769 interventional ones that give a count, is one of 81 that started in 2025, is one of 195 with no phase, and was the 781st registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

205 of the 913 studies in Diabetes Mellitus, Type 2 with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 913 studies in Diabetes Mellitus, Type 2 with a site in China, or all of them as a file.
02

Study summary

This study aims to test whether a communication strategy called "linguistic nudging" can help doctors and patients with type 2 diabetes make better treatment decisions together, and whether this improves patients' ability to manage their condition.

What will happen in the study? - 250 adults with type 2 diabetes from Xiang'an Hospital (Xiamen) will be randomly assigned to one of two groups:

Intervention group:Doctors will receive special training in "linguistic nudging" techniques to encourage shared decision-making. Patients will use a mobile app to record medication preferences, and doctors will adjust advice based on these preferences.

Control group:Patients will receive standard diabetes care without these additional strategies.

- All participants will be followed for 6 months.

What is the study aiming to find out?

The main goal is to see if patients in the intervention group:

Better follow medication plans Improve blood sugar monitoring Have better blood sugar control Feel more satisfied with doctor-patient communication

Why is this important? Good self-management is key to controlling diabetes, but many patients struggle with it. Effective communication during shared decision-making may empower patients to manage their condition day-to-day with greater confidence.

Patient safety and rights:

Participation is completely voluntary All personal information will be kept strictly confidential Medical support will be provided if any health problems occur during the study Participants may withdraw at any time

This research has been approved by the Ethics Committee of Xiang'an Hospital (Approval date: October 2025).

03

Conditions studied

  • Diabetes Mellitus, Type 2
  • Physician-Patient Relations
  • Self-management

Keywords

  • Linguistic Nudging
  • Shared Decision Making
  • Randomized Controlled Trial
  • Mobile Health Application
  • Chinese Population
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of type 2 diabetes
  • Age ≥ 18 years
  • Normal cognitive function (assessed by Mini-Cog score ≥ 3)
  • Basic smartphone operation ability (can independently use WeChat)
  • Willing to participate and sign

Exclusion criteria

Exclusion Criteria:

  • Severe acute complications (e.g., ketoacidosis, hyperosmolar coma)
  • Documented cognitive impairment (dementia, Alzheimer's, etc.)
  • Currently participating in other clinical trials
  • \< 6 months
  • Pregnancy or lactation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
280 participants (actual)

Study arms

  • Experimental
    Linguistic Nudging Group

    Receives communication training + preference app

    Behavioral: Linguistic Nudging Training · Device: Medication Preference App · Other: Standard Diabetes Care

  • Other
    Standard Care Group

    Receives routine diabetes management only

    Other: Standard Diabetes Care

Interventions

  • BehavioralLinguistic Nudging Training

    Physicians receive 4-hour communication training to optimize shared decision-making using behavioral nudging techniques

  • DeviceMedication Preference App

    Patients use WeChat-based mini-program to record daily medication preferences and concerns

  • OtherStandard Diabetes Care

    Routine follow-up visits, HbA1c monitoring, and basic health education per hospital protocol

06

What researchers measure

Primary outcomes

  1. Change in Glycated Hemoglobin (HbA1c) Level

    Absolute change in HbA1c (%) from baseline to 6 months, measured by high-performance liquid chromatography (HPLC). Reflects average blood glucose control over 3 months.

    Time frame: Baseline and Month 6

  2. Diabetes Self-Management Capacity Scale Score

    Composite score (0-100) based on validated 20-item scale assessing medication adherence, dietary control, physical activity, and blood glucose monitoring. Higher scores indicate better self-management capacity.

    Time frame: Baseline, Month 3, Month 6

  3. Shared Decision Making Questionnaire (SDM-Q-9) Score

    Patient-reported evaluation of shared decision quality using 9-item Likert scale (0-45). Assesses physician-patient collaboration in treatment choices. Higher scores indicate better shared decision-making.

    Time frame: Baseline

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2025 to primary completion in Oct 2026, 11 months.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 11 months is below that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion May 2026 → Oct 2026 and completion Jun 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2025
First posted
Aug 19, 2025
StartActual
Nov 1, 2025
Primary completionActual
Oct 17, 2026was May 2026
CompletionActual
Oct 17, 2026was Jun 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 19, 2026
Primary completion
May 31, 2026→Oct 17, 2026 (actual)
Nov 19, 2026
Study completion
Jun 2026→Oct 17, 2026 (actual)
Nov 19, 2026
Enrollment
250 (estimated)→280 (actual)
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Recruiting→Completed
    Primary completion May 31, 2026→Oct 17, 2026 (now actual)
    Study completion Jun 2026→Oct 17, 2026 (now actual)
    Enrollment 250 (estimated)→280 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07129915
Lead sponsor
Yunxuan Li
Responsible party
Yunxuan Li (Principal Investigator and Graduate Student Researcher, School of Medicine, Xiamen University, Xiamen University) — Sponsor-investigator
First posted
Aug 19, 2025
Start date
Nov 1, 2025
Primary completion
Oct 17, 2026
Completion
Oct 17, 2026
Last update
Nov 19, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion